Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Toluene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.65 |
| ▸ | ACHE | P22303 | 1/20 | 0.65 |
| ▸ | ACP3 | P15309 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toluene SCHEMBL5806354 | 1.00 | LMNA (0.65) | LMNATSHRALOX12ACHEACP3 | |
| Toluene SCHEMBL10856877 | 1.00 | LMNA (0.65) | LMNATSHRALOX12ACHEACP3 | |
| Toluene SCHEMBL28555681 | 1.00 | LMNA (0.65) | LMNATSHRALOX12ACHEACP3 | |
| Toluene SCHEMBL695755 | 1.00 | LMNA (0.65) | LMNATSHRALOX12ACHEACP3 | |
| Toluene SCHEMBL27269290 | 1.00 | LMNA (0.65) | LMNATSHRALOX12ACHEACP3 | |
| Toluene SCHEMBL1011089 | 1.00 | LMNA (0.65) | LMNATSHRALOX12ACHEACP3 | |
| Toluene SCHEMBL1931900 | 0.97 | LMNA (0.61) | LMNATSHRALOX12ACHEACP3 | |
| Toluene SCHEMBL3630619 | 0.97 | LMNA (0.61) | LMNATSHRALOX12ACHEACP3 | |
| Toluene SCHEMBL27955550 | 0.97 | LMNA (0.61) | LMNATSHRALOX12ACHEACP3 | |
| Toluene SCHEMBL29009365 | 0.97 | LMNA (0.61) | LMNATSHRALOX12ACHEACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11298367-B2 | Prodrugs of substituted triazole derivatives and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2022-04-12 | — | — | US | claimed |
| EP-3700913-B1 | PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF | BAYER AG (DE) | 2021-11-10 | — | — | EP | claimed |
| US-20200338096-A1 | PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2020-10-29 | — | — | US | claimed |
| EP-3700913-A1 | PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2020-09-02 | — | — | EP | claimed |
| CN-111225921-A | Prodrugs of substituted triazole derivatives and uses thereof | 拜耳股份公司 | 2020-06-02 | — | — | CN | claimed |
| US-20260097111-A1 | ETHER LIPIDS FOR HYPERACTIVATION OF MAMMALIAN DENDRITIC CELLS | CORNER THERAPEUTICS, INC. (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4720063-A1 | NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | Novartis AG (CH) | 2026-04-08 | — | — | EP | disclosed |
| EP-4714961-A2 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4209483-B1 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12421276-B2 | Methods of treating neurodegenerative disease with substituted n-hexanoic-l-tyrosine-l-isoleucine-(6)-aminohexanoic amide analogues | ATHIRA PHARMA, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250275991-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-09-04 | — | — | US | disclosed |
| EP-4604919-A1 | ETHER LIPIDS FOR HYPERACTIVATION OF MAMMALIAN DENDRITIC CELLS | Corner Therapeutics, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20100221269-A1 | SYNTHETIC LIPID A DERIVATIVE | UNIVERSITY OF GEORGIA RESEACH FOUNDATION, INC (US) | 2010-09-02 | — | — | US | disclosed |
| WO-2010047737-A2 | ANTIMICROBIAL INDOLINE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (KY) | 2010-04-29 | — | — | WO | disclosed |
| US-20100069441-A1 | ANTIMICROBIAL INDOLINE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | GORDEEV MIKHAIL FEDOROVICH | 2010-03-18 | — | — | US | disclosed |
| WO-2009035528-A2 | SYNTHETIC LIPID A DERIVATIVE | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| EP-1283672-B1 | ANTITUBULIN ASSEMBLY AND CELL GROWTH INHIBITOR DENOMINATED \"DIOXOSTATIN\ | UNIV ARIZONA STATE (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040122083-A1 | Antitubulin assembly and cell growth inhibitor denominated \"dioxostatin\ | ARIZONA BOARD OF REGENTS ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY | 2004-06-24 | — | — | US | disclosed |
| EP-1283672-A1 | ANTITUBULIN ASSEMBLY AND CELL GROWTH INHIBITOR DENOMINATED \"DIOXOSTATIN\ | Arizona Board of Regents, acting for and on behalf of Arizona State University (US) | 2003-02-19 | — | — | EP | disclosed |
| WO-2001084929-A1 | ANTITUBULIN ASSEMBLY AND CELL GROWTH INHIBITOR DENOMINATED 'DIOXOSTATIN' | ARIZONA BOARD OF REGENTS, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200338096-A1 | PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF | CYP4B1, AADAC, GLS | LMNA 1534/4885TSHR 1793/4885ALOX12 3571/4885 |
| US-20250275991-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | LMNA 1900/4885TSHR 3081/4885ALOX12 423/4885 |
| US-20040122083-A1 | Antitubulin assembly and cell growth inhibitor denominated \"dioxostatin\ | MCL1, TUBA1C, TUBB8 | LMNA 2780/4885TSHR 2903/4885ALOX12 4699/4885 |
| US-20100069441-A1 | ANTIMICROBIAL INDOLINE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | IDO1, IDO2, INMT | LMNA 2380/4885TSHR 4027/4885ALOX12 2647/4885 |
| US-20260097111-A1 | ETHER LIPIDS FOR HYPERACTIVATION OF MAMMALIAN DENDRITIC CELLS | TLR7, INPP5D, PLCD1 | LMNA 3757/4885TSHR 951/4885ALOX12 1241/4885 |
| US-12421276-B2 | Methods of treating neurodegenerative disease with substituted n-hexanoic-l-tyrosine-l-isoleucine-(6)-aminohexanoic amide analogues | AADAT, ABAT, IAPP | LMNA 2873/4885TSHR 2069/4885ALOX12 616/4885 |
| US-20100221269-A1 | SYNTHETIC LIPID A DERIVATIVE | DDOST, STT3A, UGCG | LMNA 2345/4885TSHR 1943/4885ALOX12 495/4885 |
| US-11298367-B2 | Prodrugs of substituted triazole derivatives and uses thereof | CYP4B1, AADAC, GLS | LMNA 1534/4885TSHR 1793/4885ALOX12 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.